Andrés Íñiguez

Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk

Philip Urban, Ian T. Meredith, Alexandre Abizaid et al. · New England Journal of Medicine · 2015 · 808 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 785 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 560 citations · Full text

Medicine, Cardiology, Surgery +17

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Marco Valgimigli, Enrico Frigoli, Dik Heg et al. · New England Journal of Medicine · 2021 · 544 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

Patrick W. Serruys, Bernard Chevalier, Yohei Sotomi et al. · The Lancet · 2016 · 538 citations · Full text

Medicine, Cardiology, Surgery +17